TickerWorth Open the interactive view →

Healthpeak Properties, Inc. (DOC) — Valuation Snapshot

Updated Sep 3, 2026 · REIT · FFO, book-value and yield view · descriptive, not a DCF, not advice

This is a REIT. A free-cash-flow DCF is structurally the wrong lens for property: heavy depreciation and continuous property capex swamp reported free cash flow, which is why REITs are valued on FFO/AFFO, net asset value and dividend yield. We show those lenses instead of a DCF number we would not stand behind.
Price
$21.03
Market cap
$14,909,161,472
52-week high
$22.95
52-week low
$15.70
Currency
USD
Exchange
NYSE

Healthpeak Properties, Inc. (DOC) is a real-estate investment trust, and a free-cash-flow discounted-cash-flow (DCF) model is structurally the wrong lens for one. A REIT's reported free cash flow is swamped by property depreciation and the continuous capital spending that maintaining a portfolio requires, which is why the industry is valued on funds from operations (FFO/AFFO), net asset value and dividend yield instead. We have the data to print a DCF number for DOC; we don't publish one because it would not mean what it appears to mean. What follows is how a REIT is actually read — descriptive, not a valuation, and not investment advice.

On the numbers we do have, DOC trades at a recent price of $21.03, a market capitalisation of about $14,909,161,472, sitting 74% of the way up its 52-week range ($15.70–$22.95), on the NYSE.

The standard alternative to a DCF is relative valuation — comparing DOC's trading multiples against a sector benchmark. Here that gives P/E of 60.1× (richer than the peer median of 31.2×); Fwd P/E of 150.2× (richer than the peer median of 38.8×); P/B of 1.8× (cheaper than the peer median of 7.0×); P/S of 5.1× (cheaper than the peer median of 10.2×); EV/EBITDA of 15.8× (cheaper than the peer median of 19.1×); Dividend yield of 5.8% (cheaper than the peer median of 4.0%). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.

The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. DOC shows a price-to-book (P/B) of 1.85 and book value of $11.38 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.

Finally, a price-based read — explicitly not a valuation. DOC is in a mixed trend, trading -8.4% from its 52-week high. Over the past year the stock is +15.7%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.

To be exact about what this page is not: we are not saying the numbers for DOC are unavailable. They are, and they are above. We are saying a discounted-cash-flow model is the wrong instrument for this kind of business, and publishing one anyway — because the inputs happen to exist — would be a precise answer to the wrong question. Refusing is the more useful answer, and it is the same rule we apply to every name in this category.

Relative valuation — DOC vs peers

MultipleDOCPeer median
P/E60.1×31.2×richer than
Fwd P/E150.2×38.8×richer than
P/B1.8×7.0×cheaper than
P/S5.1×10.2×cheaper than
EV/EBITDA15.8×19.1×cheaper than
Dividend yield5.8%4.0%cheaper than

Sector benchmark (bellwethers, not direct competitors).

Asset / book-value view

Price / book (P/B)
1.85
Book value / share
$11.38

Price-to-book compares the market price to the accounting net-asset value per share. Most useful for asset-heavy businesses, banks and insurers.

Price-based snapshot

50-day avg
$21.54
200-day avg
$18.56
From 52-wk high
-8.4%
1-year momentum
+15.7%

Price-based, not a valuation. Moving-average trend and 52-week position describe where the stock has traded — they say nothing about fair value.

Explore more

Most undervalued stocks (per our valuation) · All valued stocks · Interactive DOC view

A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is an educational tool, not a licensed investment adviser. Figures are estimates derived from public market data and can be wrong, stale or incomplete.